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ABSTRACT
IN-VITRO COMPARISON OF AEROSOL DRUG DELIVERY IN PEDIATRICS
USING PRESSURIZED METERED DOSE INHALER, JET NEBULIZER, AND
VIBRATING MESH NEBULIZER
By
Huriah H. Al Sultan
Background: Aerosol therapy has been established as an efficient form of drug
delivery to pediatric and adult patients with respiratory diseases; however, aerosol
delivery to the pediatric population is quite challenging. While some studies compare jet
nebulizer (JN), vibrating mesh nebulizer (VMN), or JN and pMDI, there is no study
comparing these three devices in pediatric and young children. The aim of this study
quantifies aerosol deposition using JN, VMN, and pMDI/VHC in a simulated pediatric
with active and passive breathing patterns.
Methods:!Each aerosol generator was placed between manual resuscitator bag
(Ambu SPUR II Disposable Resuscitator, Ambu Inc, Glen Burnie, MD) and infant
facemask (Mercury Medical, Cleanwater, FL), which was held tightly against the SAINT
model. Breathing parameters used in this study were Vt of 100 mL, RR of 30 breaths/min,
and I:E ratio of 1: 1.4.!Active and passive breathing patterns were used in this study with
aerosol device; active breathing pattern was created using a ventilator (Esprit Ventilator,
Respironics/Philips Healthcare, Murrysville, PA) connected to a dual chamber test lung
(Michigan Instruments, Grand Rapids, MI), which was attached to an absolute filter
(Respirgard II, Vital Signs Colorado Inc, Englewood, CO), to collect aerosolized drug,
connected to the SAINT model. Pediatric resuscitator bag was run at 10 L/min of oxygen
and attached to aerosol generator with facemask. In passive breathing pattern, SAINT
model was attached to test lung and ventilated using the resuscitator bag with the same
breathing parameters. Each aerosol device was tested three times (n=3) with each
breathing patterns. Drug was eluted from the filter and analyzed using spectrophotometry.
The amount of drug deposited on the filter was quantified and expressed as a percentage
of the total drug dose. To measure the differences in the inhaled drug mass between JN,
VMN, and pMDI/VHC in active or passive breathing, one-way analysis of variance (oneway ANOVA) was performed. To quantify the difference in aerosol depositions between
the two breathing patterns, independent t-test was performed. A p < 0.05 was considered
to be statistically significant.
Results:!Although the amount of aerosol deposition with the JN was the same in
passive and active breathing without any significant difference, the VMN was more
efficient in active breathing than the JN (p = 0.157 and p = 0.729, respectively).
pMDI/VHC had the greatest deposition in the simulated spontaneous breathing (p=0.013)
Conclusion: Aerosol treatment may be administered to young children using JN,
VMN, or pMDI/VHC combined with resuscitator bag. Using pMDI/VHC with
resuscitator bag is the best choice to deliver albuterol in spontaneously breathing
children. Further studies are needed to determine the effectiveness of these aerosol
generators with different type of resuscitator bag and different breathing parameters.

!

!

TABLE OF CONTENTS
Page
iii
iv
v

List of Tables
List of Figures
Abbreviations
Chapter
I. INTRODUCTION
Significance
Hypothesis
Purpose
Research Question

1
3
4
4
4

II. REVIEW OF THE LITERATURE
In Vivo Aerosol Research
In Vitro Aerosol Research

5
5
12

III. METHODOLOGY
Types of Aerosol Generator, Doses, and
Operation
In Vitro Lung Model
Active Breathing
Passive Breathing
In Vitro Measurements
Data Analysis

19
19

IV. RESULTS

24

20
20
21
22
23

V. DISCUSSION

26

References

31

!

!

!!

ii!

!

LIST OF TABLES

Tables
1.

!

Page
Mean inhaled mass percent ± SD of albuterol sulfate using JN, VMN,
and pMDI/VHC in passive and active breathing

!!

iii! !

24

LIST OF FIGURES
Figures !

Page

1.

Diagram of lung model for simulated active and passive breathing

21

2.

Organizational design of the study

22

3.

Mean aerosol percent in JN, VMN, and pMDI/VHC in passive and
active breathing patterns

25

!

!!

iv! !

ABBREVIATIONS
BPD
CF
DPI
GSD
JN
MMAD
MMD
pMDI
SVN
SAINT
SPECT
VHC
VMN
USN

!

Bronchopulmonary dysplasia
Cystic fibrosis
Dry Powder Inhaler
Geometric Standard Deviation
Jet Nebulizer
Mass Median Aerodynamic Diameter
Mass Median Diameter
Pressurized Metered-Dose Inhaler
Small Volume Nebulizer
Sophia Anatomical Infant Nose-Throat
Single Photon Emission Computed Tomography
Valved Holding Chambers
Vibrating Mesh Nebulizer
Ultrasonic Nebulizer

!!

v!

!

CHAPTER I
INTRODUCTION
Aerosol therapy has been established as an efficient form of drug delivery to
pediatric and adult patients with respiratory diseases. However, aerosol delivery to the
pediatric population is quite challenging. When dealing with infants, healthcare providers
face different factors than the adult population. For instance, factors such as anatomical
and physiological differences, choosing the right aerosol delivery device, and minimizing
stress and facemask leak are some of that affect aerosol delivery to small children.
One of the challenging factors is anatomical and physiological differences
between adults and children. Children are obligatory nose breathers until age 18 months.
According to Chua et al. (1994a), delivery of aerosol through the nose to the lower
airways is less effective than through the mouth and this might be explained by high
velocity and turbulent flow in the nose and nasopharynx area. Moreover, aerosol
deposition is influenced by children’s breathing pattern. High respiratory rate (RR) with
variable inspiratory flow, low tidal volume (Vt), and smaller airway diameter can
diminish deposition of inhaled aerosols to the lower airways in children (Fok et al., 1996).
One of the most important challenges during aerosol treatment is the child’s
acceptance and tolerance of the aerosol device and its interface. Crying, squirming, and
facemask leak can affect the total dose delivered to the lungs. A study done by Tal et al.
(1996) showed that the total lung deposition delivered by pMDI-VHC-facemask was
decreased by 6 fold in crying children (0.3%) compared to quietly breathing children
(2%). Another in-vivo study done by Schuepp et al. (2009) showed that mean lung
!
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deposition was higher in quietly breathing children (48.6%) than in children crying
during inspiration (20.0%). During crying, most of the drug is deposited in the upper
airways and the pharynx, which is then swallowed.
Choosing the right aerosol device with its interface is vital for optimizing aerosol
treatments in young children. Aerosol generators used for the treatment of infants can be
categorized into nebulizers, pressurized metered-dose inhalers (pMDI), and dry-powder
inhalers (DPI). There are three types of nebulizers; jet nebulizers (JN), vibrating mesh
nebulizers (VMN), and ultrasonic nebulizers (USN). JN and pMDI/spacer are commonly
used for aerosol drug delivery to children. However, lung deposition in young children
inhaling from conventional nebulizers is low and has been shown to be between 0.1%
and 8% (Schuepp et al., (2009). Another in-vivo study done by Fok et al. (1996), showed
less than 2% of aerosol was deposited in the lungs by pMDI with spacer and JN in
spontaneously breathing and ventilated infants with bronchopulmonary dysplasia (BPD).
Vibrating mesh nebulizer is a novel device that generates a higher dose of
uniformed small particles, has negligible residual volume, and faster rate of nebulization
than traditional nebulizers, which consequently improves drug deposition (Dolovich et al.
(2011)). Ari et al. (2010) compared JN and VMN in two different positions in
mechanically ventilated adult and pediatric models. They found that VMN had higher
deposition than JN at all positions (2-4 fold). An in-vitro study compared two different
types of VMNs, Aeroneb Go/Idehaler and MicroAir, to JN PARI LC Star. Aeroneb Go
VMN showed the greatest performance in terms of pulmonary aerosol delivery and
optimal particle size (Coates et al. (2011).
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Facemasks, blow-by, hood, high-flow nasal cannula, mouthpiece, and spacer or
valved-holding chambers (VHC) are different interfaces used with aerosol devices in
infants. A facemask is the most common interface used in infants; however, facemask
seal and leak around the facemask is a common problem that affects drug delivery.
Esposito-Festen et al. (2004) and Erzinger et al (2007) showed that even a small leak
around the facemask could cause significant reduction in aerosol delivery to infants.
Therefore, an optimal seal with light pressure on the face could minimize the leak and
improve aerosol delivery. In some clinical settings manual resuscitator bag is being used
to deliver aerosol treatments in an effort to improve aerosol deposition. For instance,
some pediatric hospitals in the southeast use resuscitator bag with jet nebulizer to provide
continuous positive pressure (CPAP) in order to open collapsed lungs and relive
bronchospasm.
Aerosolized drug delivery is more challenging in the pediatric population.
Identification of factors of efficient drug delivery and challenges of delivering aerosol to
children can optimize aerosol delivery to this age group. Thus, extensive research needs
to be conducted to identify the most effective delivery device and the best way to deliver
medical aerosol therapy in infants.
Significance:
Different types of aerosol devices have been used to administer aerosolized drugs
for children with pulmonary diseases such as asthma, cystic fibrosis (CF), and BPD. JNs,
pMDIs, and VMNs are the most common type of aerosol devices used in children. Even
though there are some studies comparing either JNs and VMNs or JN and pMDI, there is
no study comparing these three devices in pediatric and young children.
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Any new device or intervention introduced into clinical practice should be
supported by strong research evidence. For example, manual resuscitator bag combined
with aerosol devices is being used in some clinical settings even though the effect of this
combination on aerosol deposition is unknown. Therefore, more information is needed to
determine the effect of using resuscitator bag on aerosol delivery.
Since this study also determines the difference in aerosol deposition between
active and passive breathing, it would help health care providers to select the best aerosol
delivery device to use with manual resuscitator bag in pediatrics.
Hypothesis:
Aerosol deposition with each aerosol generator varies in active and passive
breathing patterns. Simulated active breathing pattern would have different aerosol
deposition than a passive breathing pattern.
Purpose:
The aim of this study is to quantify aerosol deposition using pMDI, jet nebulizer,
and vibrating mesh nebulizer in a simulated pediatric model with active and passive
breathing patterns.
Research Questions:
1. What is the efficiency of aerosol therapy through manual resuscitator bag used with
jet nebulizer, vibrating mesh nebulizer, and pMDI?
2. What is the difference in delivery efficiency of aerosol therapy between simulated
active and passive breathing patterns?
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CHAPTER II
REVIEW OF THE LITERATURE
Introduction:
This is a review of the literature for the articles published in the area of aerosol
therapy for pediatrics. Literature was obtained using different terms such as aerosol
delivery, aerosol deposition, nebulizers, vaporizers, metered dose inhaler, pMDI, jet
nebulizers, small volume nebulizers, SVN, and vibrating mesh nebulizers in pediatrics.
For aerosol delivery through facemask, terms such as facemask, facemask leak, and
facemask in pediatrics were used. For manual resuscitator bag terms such as ambu bag,
flow-inflating bag, self-inflating bag, and resuscitation bag for pediatrics were used. All
research was obtained from PubMed, CINAHL Plus with Full Text, and MEDLINE with
Full Text. The articles included in the review of the literature ranged from1990 to 2011.
All articles were written in English and peer-reviewed.
In-Vivo Aerosol Researches:
Mallol et al. (1996) conducted a study on 20 asymptomatic infants aged between
3 and 24 months with CF. They used radiolabelled aerosols generated by jet nebulizer to
quantify the amount of deposited aerosol in the pulmonary system. Group A, which
consisted of 10 infants, was sedated while receiving aerosol with 7.7 µm mass median
diameter (MMD) using Bennet-Twin jet nebulizer with air flow of 5.5 L/min. Group B,
consisted of 5 infants, used the same type of nebulizer while they were awake. Group C
(N=5), infants were awake; they inhaled aerosol with 3.6µm MMD administered by
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Hudson Up-Draft II jet nebulizer with airflow of 8 L/min. The aerosol deposition
was evaluated using gamma camera with closed system upon completion of nebulization.
They found that the total lung depositions for the 3 groups A, B, and C were 0.97 ±
0.35%, 0.76 ± 0.36%, and 2.0 ± 0.71%, respectively. In group C most deposition
occurred in the lung region while in group A and B the aerosol deposited in the trachea
and main bronchi. In addition, they found that the most important determinant of aerosol
deposition in the lung region was the particle size rather than demographic features and
sedation.
Amirav et al. (2002) studied 12 children, aged between one month and 14 months,
diagnosed with acute respiratory syncytial or bronchiolitis to evaluate aerosol deposition
and distribution in the lower respiratory tract. Radiolabelled albuterol was administered
through a Micromist jet nebulizer (Hudson Respiratory Care Inc.) with a facemask
connected to oxygen at 8 L/min. They used scintigraphy to evaluate the total lung and
body deposition and distribution of aerosolized medication in the lungs. They found that
10% – 12% of the drug dose exiting from the nebulizer deposited on the face with 7.8% ±
4.9% deposited in the upper respiratory and gastrointestinal tracts. In addition, they found
that 1.5% ± 0.7% of the drug dose reached to the right lung and 0.6% penetrating to the
peripheral lung zone. There was no relationship found between demographic data such as
height, weight, or body surface area, and deposition indices or clinical response.
Tal et al.(1996) performed a study on fifteen children with obstructive airway
diseases, aged between 2.5 and 5 years (mean of age 20.9 months), to examine the
amount of drug deposition in the pulmonary and gastrointestinal tracts. Seven children
were diagnosed with asthma, four children have CF, and four diagnosed with BPD.
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Gamma camera was used to assess the drug deposition immediately after administering 1
puff of radiolabelled salbutamol through pressurized metered dose inhaler (pMDI),
spacer (Aerochamber), and facemask. They found that the mean aerosol deposition was
1.28% ± 0.77% in the oropharynx, 1.97% ± 1.4% in the lungs, and 1.11% ± 2.4% in the
stomach with the remaining was trapped in the spacer.
Wildhaber et al. (1999) conducted a study to compare lung deposition between
pMDI with holding chamber (Aerochamber, Trudell Medical) and nebulizer (PARI Baby
and PARI LC Star, PARI GmbH). They examined seventeen stable asthmatic children
aged between 2 and 9 years. Treatment was administered randomly with 4 puffs of
radiolabelled salbutamol (Ventolin, 100µg/actuation) via pMDI/holding chamber or 2 ml
radiolabelled nebulized salbultamol (Ventolin, 1 mg/ml). By scanning body and lungs
with a gamma camera, they found that the mean total lung deposition for the pMDI was
5.4% (21.6µg) in children less than 4 years old and 9.6% (38.4µg) in children older than
4 years old. For nebulized treatment, mean lung deposition was 5.4% (108 µg) in younger
children and 11.1% (222 µg) in older children.
Salmon, Wilson, & Silverman (1990) studied sixteen children, nine infants were
wheezy and 7 adults were healthy, to assess the delivery of aerosol by using sodium
cromoglycate as a non-toxic marker. They delivered the drug via pMDI, facemask, and
spacer or facemask and nebulizer (an Acorn nebulizer). They measured the concentration
of sodium cromoglycate in urine to estimate the dose of drug that deposited in the lung.
They found that only 0.13% - 0.61% of the 20 mg nominal dose was found in the urine,
which represents 0.3% - 1.5% deposited in the pulmonary system.
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Fok et al. (1996), conducted a study to evaluate drug deposition in ventilated
versus non-ventilated infants, who either had BPD or at high risk of BPD, by using
radiolabelled salbutamol via pMDI or jet nebulizer. Twenty-three infants enrolled in a
randomized, crossover study; thirteen infants were spontaneously breathing and ten
infants were mechanically ventilated. For non-ventilated babies, inhaled aerosol
treatments were given through facemask attached to a nebulizer or pMDI and spacer
(Aerochamber, Trudell Medical). While in ventilated babies, treatment received through
either pMDI + spacer (MV15, Aerochamber) or a nebulizer attached to the ventilator
circuit. They found that the mean of the mass median aerodynamic diameters (MMADs)
and geometric standard deviation (GSD) of pMDI for ventilated infants were 1.88µm and
1.45µm, respectively after passing the MV15; for the spontaneously breathing infants
MMAD and GSD were 1.83µm and 1.50 µm, respectively after exiting the Aerochamber
with the mask. In addition, they found that the mean MMAD and GSD for the jet
nebulizer with the ventilated babies were 0.83µm and 1.69µm, respectively, and MMAD
of 1.01µm and GSD of 1.64µm for non-ventilated babies. For spontaneously breathing
infants, aerosol deposition in the lungs using pMDI was between 0.12 % and 2.26% and
between 0.12% and 0.66% of the initial nebulizer reservoir. For the intubated infants,
aerosol deposition in the lungs was between 0.35% and 2.12% using the pMDI, and
0.22% of the initial nebulizer reservoir.
Chua et al. (1994b) performed a study on 12 infants (median age 0.8 yrs) and 8
older children (median age 10.8 yrs) with asymptomatic CF to evaluate the effect of age
on aerosol deposition in the lungs. A Turret nebulizer with compressed air at 9 L/min was
used to administer radiolabelled normal saline via facemask for infants and facemask and
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mouthpiece for older children. Planar and single-photon emission computed tomography
(SPECT) scans were used to evaluate the deposition in the pharynx and lungs for all
children after inhalation therapy. When they used a facemask, they found that the total
lung deposition for infants was (median 1.3%, range 0.3–1.6%) and for the older children
was (median 2.7%, range 1.6–4.4%). In addition, they found that there is no difference
between mouthpiece and facemask in older children.
Ploin et al. (2000) conducted a randomized double-blinded, parallel group
equivalence trial on 64 children (range 2 -5 yrs old) with acute recurrent wheezing and a
history of at least one episode of wheezing. The aim was to determine the clinical
equality for albuterol administration between pMDI and spacer devices and nebulizer.
Sixty four children were divided into two groups of 32; one group was received pMDI
albuterol and nebulized placebo and the other group has albuterol solution through
nebulizer and then pMDI placebo. Treatment was repeated three times with an interval of
twenty minutes. Pulmonary index, hospitalization, pulse oximetry saturation, ease of use,
and acceptability were measured. They found that pMDI/spacer has the same efficacy as
the nebulizer; however, parents considered administration of albuterol by pMDI/ spacer is
easier and accepted by children.
Coates et al.(2011) performed a study on eight children and eight adults
diagnosed with CF to determine if equivalent levels of pulmonary deposition could be
achieved in shorter time using 1.5 ml of 100 mg/ml tobramycin solution delivered by a
vibrating mesh nebulizer (PARI eFlow nebulizer). All subjects instructed to inhale one of
the two formulations of radiolabled tobramycin, in which approximately 150 – 250 mBq
were added to either 5ml of tobramycin solution (60 mg/ml, TOBI1) with the PARI LC
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PLUS1 nebulizer or for the investigational PARI e-Flow (PARI GmbH), charged with
1.25 ml (six initial subjects) or 1.5 ml (all subjects) of tobramycin solution (100 mg/ml).
Blood samples were taken after 60 min to measure the amount of tobramycin in the
serum. The PARI LC PLUS delivered 45.4 mg (mean) to the lungs in 17.0 ± 2.5 min
(mean ±SD) with serum levels of 1,089 ± 388 µg/L. e-Flow delivered 46.3 mg in 4.0 ±
1.0 min with blood levels of 909 ± 458 µg/L.
Rotta et al. (2010) conducted a randomized clinical trial on 46 children (1–5 years
of age) to determine if the plasma concentrations of salbutamol, obtained during
inhalation treatment of acute asthma, are influenced by age range or by the aerosol
system used. Twenty five children received salbutamol using a pMDI with spacer (50
µg/kg), and 21 children received salbutamol by nebulization (150 µg/kg), three times
during a 1-hour period. At the end of the treatment, one blood sample was drawn and the
plasma was stored for later determination of salbutamol concentration (liquid
chromatography). Salbutamol plasma concentrations were compared in two age groups
(≤2 years and >2 years of age). The type of device used (pMDI or nebulizer) and the need
of hospitalization were also tested. No differences were detected regarding either the
aerosol delivery system used or the need for hospitalization in relation to the plasma
concentrations of salbutamol. However, higher plasma levels were found in children>2
years vs. children ≤2 years.
Schueepp et al. (2009) recruited 10 asymptomatic asthmatic children (mean age of
20.3 months and range between 6 and 41 months) to determine lung deposition and its
ratio to oropharyngeal deposition. They used radiolabelled budesonide (Budesol
200µg/ml with MMD 2.6 µg) delivered through a modified vibrating membrane
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nebulizer (e-Flow® Baby, PARI GmbH). Each child inhaled 2 puffs of Ventolin
(Salbutamol, 100µg/actuation, Glaxo Smithkline, Australia) through a holding chamber
(Babyhaler®, Glaxo Smithkline, Australia) prior to nebulization. Nebulized treatment
administer using a tightly fitting facemask (Sure Seal®, 1237 pediatric, Hudson RCI.), a
round shaped facemask with an inflatable rim. All patients were scanned using
scintigraphy and lung deposition was measured, which was expressed as a percentage of
the emitted dose, and its ratio to oropharyngeal deposition were calculated. Mean lung
deposition (SD) was higher in quietly breathing children 48.6% (10.5) than in children
crying during inspiration 20.0% (10.9). Mean lung deposition to oropharyngeal
deposition ratio (SD) in quietly breathing children was1.0 % (0.3) and in crying children
was 0.3 % (0.2).
Erzinger et al.(2007) conducted an in vivo study on eight asymptomatic children
with recurrent wheezes aged between 18 and 36 months. Their aim was to verify that a
small air leak in the facemask can significantly reduce the efficiency of aerosol drug
delivery. Four children inhaled 2 mL of radiolabeled salbutamol solution (Ventolin, 1
mg/ mL) from an open vent-assisted nebulizer (Pari Baby with Pari facemask no.2); and
four children inhaled 4 puffs radiolabeled pMDI (Ventolin, 100 µg/puff) via a plastic
spacer (Aerochamber with an Aerochamber 2nd generation facemask, Trudell Medicine).
Drug deposition was quantified with a gamma camera and lung deposition was expressed
as percentage of the total dose. They found that in 2 children with a facemask leak, lung
deposition for pMDI and nebulizer were 0.2% and 0.3%, respectively. In another 2
children, who were screaming and without facemask leak, lung deposition for pMDI and
nebulizer were 0.6% and 1.4%, respectively. In addition, they found that in quietly
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breathing children (n =4) without facemask leak was 4.8% for pMDI and 8.2% for
nebulizer. Moreover, face deposition ranged between 2.6% and 8.4% with mask
deposition ranged between 0.8% and 5.2%.
Esposito-Festen et al.(2006) conducted a study to investigate the feasibility of
aerosol administration by means of pMDI-spacer in sleeping young children. Thirty
children (age range, 6 to 23 months) with recurrent wheeze over a period of 3 weeks were
recruited. They inhaled 1 puff of budesonide aerosol (Pulmicort, 200 µg; AstraZeneca)
while awake and 1 puff during sleep. Filters positioned between the chamber and the
facemask trapped the budesonide aerosol. Parents scored the child’s asthma symptoms,
degree of cooperation, and feasibility of administration on diary cards. They found that,
the mean filter dose, which was expressed as the percentage of the nominal dose, while
awake was 47%, and during sleep was 16%. The median within-subject dose variability
while awake was 50%, and during sleep it was 110%.
In-Vitro Aerosol Researches:
Coates et al.(2011) conducted an in vitro study to select the best nebulizer system
for delivering magnesium sulfate (MgSO4) that would be effective over the entire age
range. They compared different types of vibrating mesh nebulizers such as MicroAir
vibrating-mesh nebulizer (Omron) and the Aeroneb Go (Aerogen) with the Idehaler
valveless holding chamber to jet nebulizer the Pari LC Star (Pari). They diluted 2 ml of
MgSO4 in 7 ml sterile water then added 1 ml of albuterol (5mg/ml) and they put 6 ml in
each nebulizer from that solution. They found that the Pari LC Star had an appropriate
particle size distribution but a very slow aerosol output rate. Omron MicroAir has the
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slowest output rate with the largest particle size while Aeroneb Go/Idehaler system
demonstrated the superior performance with optimal particle size.
Johnson et al. (2008) performed an in vitro study to evaluate the efficiency of
vibrating mesh nebulizers and jet nebulizer in delivering inhaled recombinant human
DNase I (rhDNase). They compared vibrating mesh nebulizer (MicroAir, Omron) to a jet
nebulizer (Pari LC+ with the Pari ProNeb Ultra compressor). They used a respirator
pump (Harvard Apparatus) connected to simulated human lung system to determine the
total amount of nebulized rhDNase. In addition, they used an exhalation valve, such that
aerosol samples were collected onto a bacteria/virus filter (Respirgard, Marquest Medical
Products). The total aerosol delivered from both nebulizers was collected at the filters (5
of each), respiratory rate of 12/min, and tidal volume of 500 ml. For MicroAir the
MMAD was 4.3µm and GSD was 2.8µm, which was equivalent to Pari LC (MMAD
4.2µm, GSD 2.7µm). However, MicroAir was 88% more efficient than Pari LC with less
nebulization time (6.1 min vs. 7.2 min).
Laube et al. (2010) conducted a study to quantify deposition and distribution of
aerosolized albuterol in the nose and lungs by a pneumatic nebulizer using 4 copies of the
Sophia Anatomical Infant Nose-Throat (SAINT) model of a nine month old child. In
addition, they aimed to measure the amount of aerosol that escaped into the environment,
which represents the possible exposure to the care providers. They used radiolabelled
albuterol that was generated by an IP nebulizer (IPI Medical Products) at flow of 10.5
L/min from air compressor. A funnel shaped facemask was connected to 15 cm long
corrugated tube, which was attached to the nebulizer. Aerosol was delivered over a thirty
seconds period. A computer operated breathing simulator (PARI breath simulator, PARI
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GmbH) was used to control the breathing process with respiratory rate of 15 breaths over
30 seconds. The duty cycle was 0.45 seconds. Inspiratory time of 0.90 seconds and
expiratory time of 1.1 seconds were used. They used three different tidal volumes 50 ml,
100 ml, and 200 ml. Each model was surrounded with a bag to quantify the amount of
aerosolized medication that escaped into the environment. They found that lung
deposition was the same for all tidal volumes with an average of 7.17 ± 0.01%, 9.34 ±
0.01%, and 9.41± 0.02% at tidal volumes of 50 ml, 100 ml, and 200 ml, respectively.
However, with increasing tidal volume from 50 ml to 200 ml, nose deposition increased
significantly. Aerosol escaped into the environment was higher with tidal volume of 50
ml (71.99 ± 0.02%) compared to 200 ml (53.81 ± 0.04%)
Schüepp, et al., (2005) conducted an in vitro study to investigate the interaction
between infant’s airway anatomy, breathing patterns, and particle size on deposition of
nebulized aerosol to determine the optimal particle size for infants. They used budesol
(nebulizer solution of budesonide) delivered using a perforated vibrating membrane
nebulizer (e-Flow Baby functional prototype) through an upper airway cast of a 9-monthold infant (SAINT-model). Particle size was measured at a fixed RR of 30 breaths/min
and different Vt of 50, 100, and 200 ml, and at a fixed Vt of 100 mL and different RR of
30, 60, and 78 breaths / min, respectively. Lung deposition, expressed as a percentage of
the nominal dose (range 5.8 - 30.3%), decreased with increasing Vt and with increasing
RR. MMAD (range, 2.4-3.4µm) after passage through the upper airway showed a
negative correlation with increasing Vt and with increasing RR. Particles available as
lung region for all simulated breathing pattern showed a particle size distribution with a
MMAD of 2.4µm and GSD of 1.56µm.
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Janssens et al. (2004) performed a study to measure the influence of tidal volume
(Vt) respiratory rate (RR) and pMDI/spacer combination on aerosol deposition of 4 types
of infants’ pMDI/spacer combinations. A SAINT model was connected to a breathing
simulator with infant breathing parameters of duty cycle: 0.42, Vt: 25, 50, 75, 100, 150,
200 ml (RR: 30 breaths/min); and RR: 20, 30, 42, 60, 78 breaths/min (Vt: 100 mL).
pMDI/spacers used were: budesonide 200 µg/Nebuchamber®, fluticasone 125
µg/Babyhaler® and both budesonide and fluticasone with Aerochamber®. Spacer output
was measured by placing a filter (Vital Signs®) between facemask and spacer and lung
dose was assessed by a filter positioned between the model and breathing simulator.
Particle size distribution of lung dose was measured with impactor (Graseby Anderson)
using three-way glass connection. Spacer-output was significantly increased with
increasing Vt for all pMDI/spacers; however, there was no significant influence of RR on
spacer types. Lung doses initially increased from Vt = 25 to 50 mL (Nebuchamber,
Aerochamber) or to 100 mL (Babyhaler) and then decreased, with increasing Vt and RR.
Lung doses of fluticasone were 1.5–6-fold higher compared with budesonide, irrespective
of spacer type. MMAD decreased with increasing Vt and RR.
Esposito-Festen et al. (2004) performed an in vitro study to investigate the
relation between size and position of a mask leak on spacer output and lung dose. They
used an upper-airway model (SAINT model, Erasmus MC), which was attached to an
infant breathing simulator with Vt 100 ml, RR 30 breaths/min, and duty cycle of 0.42.
200µg budesonide (Pulmicort®, AstraZeneca) was administered via spacer
(NebuChamber®, AstraZeneca), which was connected to a round-shaped resuscitation
facemask (Galemed®). Facemasks with different leaks, were located close to the nose or
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to the chin, ranging from 0.05, 0.1, 0.16, 0.2, 0.3, 0.4, 0.5, 1, to 1.5 cm2 were examined.
Spacer output was measured by placing a filter (MQ303, Marquest®) between
pMDI/spacer and facemask. Lung dose was measured by placing another filter between
the SAINT model and breathing simulator. Budesonide was quantified by highperformance liquid chromatography (HPLC), and expressed as percentage of the nominal
dose. They found that for leaks from 0 to 1.5 cm2, mean spacer output doses for the nose
and the chin position ranged between 50% and 0%; leak position did not affect the spacer
output. For leaks from 0 to1.5 cm2, mean lung doses for the nose and chin position
ranged between 10% and 0. However, lung deposition for leaks in the chin position was
greater compared to the nose position.
Sangwan et al. (2004) performed an in vitro study to quantify facial and eye
aerosol drug deposition in a two-year-old child’s face model facsimile (Massachusetts
Institute of Technology) with breathing parameters of: Vt 50 mL, RR 25 breaths/min, and
duty cycle of 0.40 Aerosol delivery and facial deposition of radiolabeled saline test
aerosols were delivered through jet nebulizer with a filter placed in the orophyarynx. A
child’s face facsimile was attached to a piston pump (Harvard Pump). Seven
commercially available facemasks (Laerdal, Laerdal Medical Corp.; Sealflex, Caradyne
Ltd. Ferraris Panda, Ferraris Medical Ltd. PARI Baby & PARI Bubble, PARI Respiratory
Equipment, Inc.; Salter, Salter Labs, A Hudson, Hudson Respiratory Care, Inc.) in
combination with three jet nebulizers (Pari LC Plus, PARI Respiratory Equipment, Inc.
MistyNeb, Allegiance, and AeroTech II, CIS-US, Inc.), were used for aerosol delivery
and found that there was a leak around all types of facemask. In addition they found that,
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from the nominal dose 2.24–5.96% of nebulizer charge was inhaled with facial deposition
of 0.44 to 2.34%, and eye deposition of 0.09 to 1.78%.
Ari et al. (2010) performed an in-vitro study to determine the influence of
nebulizer position and bias flow on aerosol drug delivery in simulated and mechanically
ventilated pediatric and adult patients. Using a jet nebulizer and vibrating-mesh nebulizer,
2.5 mg in 3 mL of albuterol sulfate were aerosolized in different positions. The first
position was 15 cm from the Y-piece for the jet nebulizer and vibration-mesh nebulizer
(VMN) was placed directly to the Y-piece. In position two, jet nebulizer attached prior to
the heated humidifier with 15 cm of large corrugated tube, and the VMN placed at the
humidifier inlet. In adult and pediatric simulations a ventilator with heated humidifier
was used. Adult ventilator parameters include Vt 500 mL, RR of 20 breaths/min, peak
inspiratory flow of 60 L/min, PEEP of 5 cmH2O, and descending ramp flow waveform.
For the pediatric simulation ventilator settings were Vt of 100 mL, RR of 20 breaths/min,
inspiratory time (Ti) of 1 second, and PEEP of 5 cmH2O. Two different bias flows of 2
and 5 L/min were used. Endotracheal tube with 8-mm inner diameter was used for adult
and 5-mm for pediatric. Each aerosol device was run three times at both positions then
the drug was eluted from the filter and analyzed using spectrophotometry. The amount of
drug deposited on the filter was measured and expressed as a percentage of the nominal
dose. They found that higher bias flow reduced drug delivery and placing the nebulizer
prior to the humidifier increased drug delivery with both nebulizers. Moreover, VMN
was more efficient than jet nebuilzer at all positions and in both lung models (P<0.05).
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Summary:
Effective aerosol delivery to infants and children is challenging. Several
considerations should be taken into account when selecting the administration device. JN
is as efficient as pMDI with spacer. Nevertheless, some in-vitro studies advocate that
VMN is more efficient than JN or pMDI with spacer. In addition, facemask is the most
common interface to use for aerosol administration for infants and children less than 3
years old. Many studies suggest that even a small amount of leak around the facemask
could lower the aerosol deposition in the lungs.
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CHAPTER III
METHODOLOGY
Types of Aerosol Generators, Dose, and Operation
Three types of aerosol generator (JN, pMDI, or VMN) were placed between
manual resuscitator bag (Ambu SPUR II Disposable Resuscitator, Ambu Inc, Glen
Burnie, MD) and infant facemask (Mercury Medical, Clearwater, FL). In all runs, the
facemask was held firmly against the SAINT model, to minimize facemask leak.
Jet nebulizer (Misty-neb, Allegiance Healthcare, McGaw Park, Illinois) is a
pneumatic Bernoulli type nebulizer. The nebulizer was connected to a pediatric facemask
with a T-piece adaptor, which was attached to the manual resuscitator bag. The jet
nebulizer was operated with air at a flow of 8 L/min. During nebulization, the SAINT
model was kept in a supine position. Albuterol sulfate (2.5 mg) (Nephron
Pharmaceuticals Corporation, Orlando, FL) in 3 ml normal saline was placed in the
medication reservoir of the jet nebulizer. In each experiment, the jet nebulizer was run
continuously until sputter (5 minutes).
Vibrating mesh nebulizer (Aeroneb Solo, Aerogen, Galway, Ireland) uses
electricity to vibrate an aperture plate (containing 1,000 funnel-shaped holes) at 128 kHz.
The vibrating-mesh produces aerosol through the holes by means of a micro-pumping
action. The emitted dose of the vibrating mesh nebulizer can exceed 90% of the dose,
with a residual drug volume of 0.1– 0.3 mL. The aerosol plume from the vibrating mesh
is relatively low velocity, compared to the plume from a jet nebulizer or metered-dose
inhaler.
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pMDI albuterol sulfate (ProAir HFA, Teva Specialty Pharmaceutical, Atlanta,
Georgia) with a manufacture estimated dose of 108 µg/ puff was actuated into VHC
(Aerochamber MV, Trudell Medical International, London, Canada) with a pediatric
facemask. pMDI/VHC with facemask was attached to SAINT model, which was kept in
upright position by an elbow adapter to keep the pMDI in upright position during the
administration. Each pMDI canister was warmed to hand temperature, well shaken, and
primed using the standard boot supplied by the manufacturer before each experimental
run. A total of 4 puffs were actuated at the beginning of inspiration with an interval of 30
seconds.
In Vitro Lung Model:
!

Breathing parameters used in this study were Vt of 100 mL, RR of 30 breaths/

min, and I:E ratio of 1:1.4 (Amsallem et al., 2008; Stick, 1996). These breathing
parameters were based on the reference values for a 10 Kg 9 months old (Amsallem et al.,
2008; Stick, 1996).
Two breathing patterns were used in this study active and passive breathing
patterns. Active breathing pattern is placing the mask firmly over the model while it is
spontaneously breathing (with no mechanical assistance). Passive is using the same
model but manually assisting ventilation with the resuscitator bag.
Active Breathing:
As shown in Figure 1, pediatric spontaneous breathing was created using a
ventilator (Esprit Ventilator, Respironics/Philips Healthcare, Murrysville, PA) connected
to a dual chamber test lung (Michigan Instruments, Grand Rapids, MI), which was
attached to an absolute filter (Respirgard II, Vital Signs Colorado Inc, Englewood, CO),
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to collect aerosolized drug, which was connected to SAINT model. Pediatric resuscitator
bag was run at 10 L/min of oxygen and attached to aerosol generators with facemask.

pMDI/VHC

Vibrating Mesh
Nebulizer

Jet Nebulizer

Dual Chamber Test
Lung

Figure 1. Diagram of lung model for simulated active and passive breathing
patterns
Passive Breathing:
After the ventilator was disconnected, the SAINT model, connected to the test lung
(Michigan Instruments, Grand Rapids, MI), was manually ventilated with the resuscitator
bag during aerosol administration. The same breathing parameters were used.
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In Vitro Measurements:
As shown in Figure 2, each aerosol device was tested three times (n=3) with each
breathing pattern. The deposited drug was collected and measured using an absolute filter.
On completion of each experiment the filter was removed, labeled, and capped. The drug
was eluted from the filter with 0.1 M normal hydrochloride acid with gentle agitation for
3 min. Drug concentration was analyzed using spectrophotometry (Beckman Instruments,!
Fullerton, CA) at a wavelength of 276 nm. Wavelength accuracy was determined by

calibrating the spectrophotometry before the trials and set to zero, using the solvent alone
before each analysis. Albuterol eluted from the filter, measured, and expressed as a
percent from the original dose. In order to minimize interoperator variability, the same
operator performed all pMDI actuations and ambu bagging.

Aerosol Drug Delivery Using Ambu Bag

Active Breathing

Passive Breathing

JN

pMDI

VMN

JN

pMDI

VMN

n=3

n=3

n=3

n=3

n=3

n=3

!

Figure.2 Organizational design of the study
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Data Analysis
The amount of drug deposited on the filter was quantified and expressed as a
percentage of the total drug dose. The means and standard deviations were calculated for
each component of the total inhaled drug mass percent. One-way analysis of variance
(one-way ANOVA) was performed to measure the differences in the inhaled drug mass
between JN, VMN, and pMDI/VHC in active or passive breathing. Independent t-test
was performed to quantify the difference in aerosol depositions between the two
breathing patterns. A p < 0.05 was considered to be statistically significant.
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CHAPTER IV
RESULTS
The mean ± SD percent of the nominal dose of inhaled albuterol sulfate deposited
on the filter for each aerosol device are shown in Table 1.
Table1. Mean inhaled mass percent ± SD of albuterol sulfate using JN, VMN, and
pMDI/VHC in passive and active breathing
Aerosol Device

Passive Breathing

Active Breathing

p-values

JN (%)

2.57 ± 0.34

2.45 ± 0.46

0.729

VMN (%)

5.99 ± 1.28

7.62 ± 1.01

0.157

pMDI/VHC (%)

19.55 ± 1.60

27.84 ± 2.52

0.013

p-values

0.0001

0.0001

Effect of aerosol Device on Drug Delivery Efficiency
In both breathing patterns, passive and active, the mean inhaled percent of
albuterol delivered by pMDI/VHC was superior to the other aerosol device, JN and VMN
(p = 0.0001). Aerosol delivery efficiency of VMN was > 2 fold greater than the JN (p =
0.0001); however, pMDI/VHC had a greater proportion of lung deposition than VMN in
both passive and active breathing.
Effect of Breathing Pattern on Aerosol Delivery
Although the percent of aerosol deposition with the JN was the same in passive
and active breathing without any significant difference, the VMN was more efficient in
active breathing than the JN (p = 0.157 and p = 0.729, respectively). pMDI/VHC had the
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greatest deposition percent in the simulated spontaneous breathing (p = 0.013). However,
VMN delivered more drug mass as shown in Figure 3.

!

Figure 3. Mean aerosol inhaled mass in JN, VMN, and pMDI/VHC in passive and active
breathing. ! indicates significant difference (p > 0.05)
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CHAPTER V
DISCUSSION
Aerosol therapy has been established as a common form of drug delivery to
pediatric and adult patients with pulmonary diseases; however, aerosol delivery is more
challenging in the pediatric population. According to the findings of this study, albuterol
delivery as percent of dose was significantly higher with pMDI/VHC in both breathing
patterns. In addition, the type of breathing pattern, passive versus active, has an impact on
aerosol drug delivery even though it was not significant in JN and only a trend with
VMN.
Effect of aerosol Device on Drug Delivery
The most surprising finding of this experiment was the magnitude of aerosol
deposition efficiency with the pMDI/VHC. The percent of dose deposited with the
pMDI/VHC was consistently greater than either VMN or JN with both breathing patterns.
In terms of drug mass delivered distal to the trachea of the model, the VMN was 2-4-fold
greater than the JN; and 50% greater than pMDI with VHC. Unlike the JN, the VMN
delivered more drug with active rather than passive breathing.
The results of JN and VMN from this study were consistent with Ari et al. (2010)
who studied delivery via endotracheal tube during pediatric mechanical ventilation. They
reported that the JN (3.8 – 5.2%) was less efficient than VMN (8.4 – 13.6%) in their
mechanically ventilated pediatric model, however the absolute inhaled percent of
albuterol delivered by VMN and JN were higher than our findings. The Vt used in both

!

!

26!

studies was the same; however, they used a RR of 20 breaths/min, Ti of 1 second, and I:E
of 1:2 as opposed to RR of 30 breaths/ min, Ti of 0.9 second, and I:E of 1:1.3 used in this
study. Their I:E ratio and not passing through an airway model may account for
substantial increase in efficiency.
The inhaled mass percent of JN of 2.57± 0.34% and 2.45 ± 0.46% of nominal
dose in passive and active breathing were lower than those reported by Laube et al.
(2010). They reported a percent of inhaled dose of 9.39 ± 0.01% of the emitted dose.
They used the same breathing parameters; however, aerosol was administered using IP
JN through a 15-cm corrugated tube attached to a funnel-shaped facemask and run by air
at 10.5 L/min. In the present study, the MistyNeb JN was directly attached to a pediatric
facemask from one side and resuscitator bag form the other side and run by air at 8 L/min
until sputter. It is difficult to compare % of emitted dose to % of nominal dose, as jet
nebulizers may have > 1 mL of residual drug volume remaining at end of dose. If Laube
timed the dose, the emitted dose may be much smaller than running the nebulizer to
sputter, so deposition as a % of emitted dose might be even greater.
The results of this study were different than the results of Janssens et al. (2004)
reporting a maximum percent of inhaled fluticasone HFA pMDI with AeroChamber of
16% at Vt of 50 mL and RR of 30 breaths/min. ProAir HFA combined with
AeroChamber MV was used in this study with inhaled mass percent of 19.55 ± 1.60 and
27.84 ± 2.52 in passive and active breathing, respectively.
Effect of Breathing Pattern on Drug Delivery
In this study albuterol delivery was lower in passive breathing pattern than active
breathing. According to Dolovich et al. (1977), intermittent positive pressure breathing
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(IPPB) delivered a mean of 32% less aerosol to the lung than did quiet breathing caused
by rapid flow rate delivered by IPPB in contrast to a continuous steady flow rate
delivered with quiet breathing. Fink et al (1996), compared albuterol delivery between
controlled mechanical ventilator breaths and spontaneous breaths through the ventilator
circuit and reported 30% greater aerosol delivery during simulated passive spontaneous
breaths than during controlled breaths at equivalent tidal volumes. The mechanism of
reduced aerosol delivery with passive breathing is unclear. A possible rationalization
could be that spontaneous breathing, which pulls gas through the upper airway produces
more laminar flow toward the bronchi, as opposed to the ventilator pushing air into the
lungs.
Using a manual resuscitator bag with aerosol delivery may improve drug
deposition in the lungs. According to Lugo et al. (2004) the reduction of the duration of
manual ventilation after pMDI actuation significantly reduces albuterol delivery in
neonatal ventilator lung model. For instance, they used a cone-shaped ACE spacer, and
placed it horizontally between the endotracheal tube and a bag-valve-mask, and pMDI,
which was actuated prior to the inspiration, followed by 5, 15, or 30 manual breaths/min.
Albuterol delivery was 2.3 ± 0.5%, 3.6 ± 1.8%, and 5.1 ± 1.3% after 5, 15, and 30 manual
breaths, respectively. The results of this study, using pMDI/VHC with passive and active
breathing patterns, were higher than the aforementioned study. They used
chlorofluorocarbon (CFC) pMDI with spacer to administer aerosol to mechanically
ventilated neonatal lung model, as opposed to using HFA pMDI/VHC, JN, and VMN
with passive and active breathing in this study. The results of their study apply to
extremely-low-birth-weight infants, who weigh 1 Kg and who have Vt of approximately
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7 mL/Kg, and may not apply to larger infants. In contrast,!the parameters used were
within the reference values appropriate for a 9-month-old 10-kg baby.
Clinical Implication
For a spontaneously breathing infant administration of aerosol with the assistance
of manual resuscitator bag does not increase drug delivery.!!When applying aerosol by
mask to small children with spontaneous breathing and manual ventilation pMDI/VHC
was more efficient than other devices tested. Not only is aerosol administration via pMDI
quick, which consists of two or more inhalations at 15 to 30 second intervals requiring
seconds rather than minutes as with nebulizers, but also it is more efficient than other
nebulizers. Moreover, albuterol administration via pMDI is a very common medication
used practice. According to Ballard et al. (2002), 57% of 80 institutions used pMDI to
administer albuterol to intubated newborns.
Limitations and Future Research
Although this study provides an insight into the best device to deliver aerosol to
young children when using a manual resuscitator bag, findings may vary with different
breathing patterns. For example, when children are in stress or crying, this may further
reduce drug deposition. Different age or different type of resuscitator bag such as flow
inflating bags may also have effects on aerosol delivery. Further studies with different
breathing patterns would help to provide additional guidance to clinicians in evaluating
the best method to optimize aerosol delivery with pediatric patients. In addition, an invivo model may provide more clinical information such as clinical response.
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Conclusion:
Aerosol treatment may be administered to young children using JN, VMN, or
pMDI/VHC combined with resuscitator bag. Using pMDI/VHC is the most efficient
method to deliver albuterol via resuscitator bag in spontaneously breathing children.
However, administration of aerosol therapy with assistance of a manual resuscitator bag
does not increase drug delivery for spontaneously breathing children. Further studies are
needed to determine the effectiveness of these aerosol generators with different type of
resuscitator bag and different breathing parameters.
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